Elizabeth J Thompson1, Daniel K Benjamin2, Rachel G Greenberg1,3, Karan R Kumar1,3, Kanecia O Zimmerman1,3, Matthew Laughon4, Reese H Clark5, P Brian Smith1,3, Christoph P Hornik6,7. 1. Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA. 2. Department of Economics, Clemson University, Clemson, South Carolina, USA. 3. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. 4. Division of Neonatal-Perinatal Medicine, UNC Hospital, Chapel Hill, North Carolina, USA. 5. The Pediatrix-Obstetrix Center for Research, Education, and Quality, Sunrise, Florida, USA. 6. Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA, christoph.hornik@duke.edu. 7. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA, christoph.hornik@duke.edu.
Abstract
BACKGROUND: Furosemide is commonly used off-label in the neonatal intensive care unit (NICU), but current dosing practices vary widely. OBJECTIVES: To describe dosing practices including route, dose, and duration of exposure to furosemide in a large number of community and tertiary NICUs across North America. METHOD: Using the Pediatrix Medical Group Clinical Data Warehouse, we identified infants who received ≥1 dose of furosemide between 1997 and 2016. We excluded infants with incomplete dosing data. We calculated average daily furosemide dose, cumulative dose, total days of exposure, and maximum daily dose. We compared dosing between infants born at <32 weeks gestational age (GA) and ≥32 weeks GA. RESULTS: A total of 18,572 infants had complete dosing data. The median (interquartile value) postnatal age at first exposure was 11 days (4, 26), the median maximum daily dose was 1.0 mg/kg (0.97, 1.6), the median average daily dose was 1.0 mg/kg (0.88, 1.1), and the median cumulative dose was 2.0 mg/kg (1.0, 4.5). The median total duration of exposure was 2 days (1, 4). A total of 177 (1%) infants received ≥4 mg/kg/day of furosemide. Infants born <32 weeks GA were an older age at initial furosemide exposure compared to those born ≥32 weeks GA: 19 versus 4 days, p < 0.001. CONCLUSIONS: Most infants received short courses of furosemide within the labeled dosing parameters. Further studies are needed to assess the safety and efficacy of furosemide in the NICU.
BACKGROUND:Furosemide is commonly used off-label in the neonatal intensive care unit (NICU), but current dosing practices vary widely. OBJECTIVES: To describe dosing practices including route, dose, and duration of exposure to furosemide in a large number of community and tertiary NICUs across North America. METHOD: Using the Pediatrix Medical Group Clinical Data Warehouse, we identified infants who received ≥1 dose of furosemide between 1997 and 2016. We excluded infants with incomplete dosing data. We calculated average daily furosemide dose, cumulative dose, total days of exposure, and maximum daily dose. We compared dosing between infants born at <32 weeks gestational age (GA) and ≥32 weeks GA. RESULTS: A total of 18,572 infants had complete dosing data. The median (interquartile value) postnatal age at first exposure was 11 days (4, 26), the median maximum daily dose was 1.0 mg/kg (0.97, 1.6), the median average daily dose was 1.0 mg/kg (0.88, 1.1), and the median cumulative dose was 2.0 mg/kg (1.0, 4.5). The median total duration of exposure was 2 days (1, 4). A total of 177 (1%) infants received ≥4 mg/kg/day of furosemide. Infants born <32 weeks GA were an older age at initial furosemide exposure compared to those born ≥32 weeks GA: 19 versus 4 days, p < 0.001. CONCLUSIONS: Most infants received short courses of furosemide within the labeled dosing parameters. Further studies are needed to assess the safety and efficacy of furosemide in the NICU.
Authors: Andrea Trembath; Christoph P Hornik; Reese Clark; P Brian Smith; Julie Daniels; Matthew Laughon Journal: J Pediatr Date: 2013-06-12 Impact factor: 4.406
Authors: Rachel G Greenberg; Sreepriya Gayam; Destiny Savage; Andrew Tong; Daniel Gorham; Ari Sholomon; Reese H Clark; Daniel K Benjamin; Matthew Laughon; P Brian Smith Journal: J Pediatr Date: 2018-12-20 Impact factor: 6.314
Authors: Wesley Jackson; Genevieve Taylor; David Selewski; P Brian Smith; Sue Tolleson-Rinehart; Matthew M Laughon Journal: Matern Health Neonatol Perinatol Date: 2018-11-19
Authors: Emily M Hsieh; Christoph P Hornik; Reese H Clark; Matthew M Laughon; Daniel K Benjamin; P Brian Smith Journal: Am J Perinatol Date: 2013-12-17 Impact factor: 3.079
Authors: Nicolas A Bamat; Elizabeth J Thompson; Rachel G Greenberg; Scott A Lorch; Athena F Zuppa; Eric C Eichenwald; Veeral N Tolia; Reese H Clark; P Brian Smith; Christoph P Hornik; Jason E Lang; Matthew M Laughon Journal: J Perinatol Date: 2022-01-24 Impact factor: 3.225